#  @lb_pharma LB Pharmaceuticals LB Pharmaceuticals posts on X about ceo, $lbrx, ipo, we are the most. They currently have [--] followers and [--] posts still getting attention that total [--] engagements in the last [--] hours. ### Engagements: [--] [#](/creator/twitter::1218231041116266497/interactions)  - [--] Week [---] -72% - [--] Month [-----] +125% - [--] Months [-----] +215% - [--] Year [-----] +7,096% ### Mentions: [--] [#](/creator/twitter::1218231041116266497/posts_active)  - [--] Week [--] +13% - [--] Month [--] +275% - [--] Months [--] +200% - [--] Year [--] +4,200% ### Followers: [--] [#](/creator/twitter::1218231041116266497/followers)  - [--] Week [--] no change - [--] Month [--] +2.40% ### CreatorRank: undefined [#](/creator/twitter::1218231041116266497/influencer_rank)  ### Social Influence **Social category influence** [stocks](/list/stocks) [finance](/list/finance) [countries](/list/countries) [exchanges](/list/exchanges) **Social topic influence** [ceo](/topic/ceo), [$lbrx](/topic/$lbrx) #2, [ipo](/topic/ipo), [we are](/topic/we-are), [release](/topic/release), [advance](/topic/advance), [reduce](/topic/reduce), [united states](/topic/united-states), [study](/topic/study), [check out](/topic/check-out) **Top accounts mentioned or mentioned by** [@kylahucik](/creator/undefined) [@endpts](/creator/undefined) [@sirsglobal](/creator/undefined) [@biotechtv](/creator/undefined) [@nasdaq](/creator/undefined) [@drugtargetrev](/creator/undefined) [@hcplivenews](/creator/undefined) [@lifescievents](/creator/undefined) [@bradloncar](/creator/undefined) [@lbpharma](/creator/undefined) [@benmcomer](/creator/undefined) [@ecnptweets](/creator/undefined) [@acnporgs](/creator/undefined) **Top assets mentioned** [LB Pharmaceuticals Inc. (LBRX)](/topic/$lbrx) [Dana Incorporated (DAN)](/topic/$dan) ### Top Social Posts Top posts by engagements in the last [--] hours "Making progress #LB102 #schizophrenia" [X Link](https://x.com/lb_pharma/status/1377628977850908682) 2021-04-01T14:28Z [--] followers, [--] engagements "We just received a Notice of Allowance from South Korea (Patent Application No. 10-2019-7018269) #Schizophrenia #patent #LB102" [X Link](https://x.com/lb_pharma/status/1395061626043256833) 2021-05-19T16:59Z [--] followers, [--] engagements "LB Pharmaceuticals Presents Results of Dopamine Receptor Occupancy Studies of LB-102 at ECNP Conference #LBPharma #Schizophrenia #ECNP2021 #mentalhealth https://www.businesswire.com/news/home/20211004005645/en/LB-Pharmaceuticals-Presents-Results-of-Dopamine-Receptor-Occupancy-Studies-of-LB-102-at-ECNP-Conference https://www.businesswire.com/news/home/20211004005645/en/LB-Pharmaceuticals-Presents-Results-of-Dopamine-Receptor-Occupancy-Studies-of-LB-102-at-ECNP-Conference" [X Link](https://x.com/lb_pharma/status/1445038462734831619) 2021-10-04T14:49Z [--] followers, [--] engagements "Nearly 50% of #schizophrenia patients fail to respond adequately to existing therapies. There is an immense need for new treatments. We aim to combat this unmet need and bring hope to those who need it most. Learn more about schizophrenia here: https://bit.ly/41d4Qjg https://bit.ly/41d4Qjg" [X Link](https://x.com/lb_pharma/status/1892227751379177909) 2025-02-19T15:00Z [--] followers, [--] engagements "This #BrainAwarenessWeek we highlight the complexity of the brain and the need for continued innovation in brain health as it relates to the development of new treatments for #psychiatric diseases like #schizophrenia. Learn more from the Dana Foundation: https://bit.ly/3IiRQOJ https://bit.ly/3IiRQOJ" [X Link](https://x.com/lb_pharma/status/1899154569201914246) 2025-03-10T17:45Z [--] followers, [---] engagements "Our CEO Heather Turner was featured in @DrugTargetRev discussing our first-in-class investigational treatment LB-102 which recently showed strong results in a Phase [--] study evaluating its potential as a new therapy for #schizophrenia. Read here: https://bit.ly/3RYnl5s https://bit.ly/3RYnl5s" [X Link](https://x.com/lb_pharma/status/1914665659138494795) 2025-04-22T13:00Z [--] followers, [---] engagements "Our lead investigator John M. Kane MD spoke to @HCPLiveNews about LB-102 our investigational treatment for acute #schizophrenia that demonstrated promising efficacy safety and tolerability in our recently completed Phase [--] clinical trial. Watch here: https://bit.ly/42Iz1hR https://bit.ly/42Iz1hR" [X Link](https://x.com/lb_pharma/status/1916855004348010996) 2025-04-28T14:00Z [--] followers, [---] engagements "Our CEO Heather Turner recently spoke with @ky_lahucik of @endpts about our IPO and how the new funding positions us to initiate a Phase [--] trial in #schizophrenia and a Phase [--] trial in #BipolarDepression in [----]. Read more: https://bit.ly/473DJZS https://bit.ly/473DJZS" [X Link](https://x.com/lb_pharma/status/1976739626430730480) 2025-10-10T20:00Z [--] followers, [--] engagements "LB Pharma Initiates Phase [--] Clinical Trial for LB-102 #LBPharma #schizophrenia #brainhealth #LB102 https://www.businesswire.com/news/home/20200122005022/en/LB-Pharmaceuticals-Announces-Initiation-Patient-Dosing-First-in-Human https://www.businesswire.com/news/home/20200122005022/en/LB-Pharmaceuticals-Announces-Initiation-Patient-Dosing-First-in-Human" [X Link](https://x.com/lb_pharma/status/1219981139332489218) 2020-01-22T13:52Z [--] followers, [--] engagements "LB Pharmaceuticals Inc Announces the Hiring of Dr. Anna Eramo as Chief Medical Officer #LBPharma #LB102 #Schizophrenia https://www.businesswire.com/news/home/20200902005783/en/LB-Pharmaceuticals-Announces-Hiring-Dr.-Anna-Eramo https://www.businesswire.com/news/home/20200902005783/en/LB-Pharmaceuticals-Announces-Hiring-Dr.-Anna-Eramo" [X Link](https://x.com/lb_pharma/status/1301191591915384833) 2020-09-02T16:13Z [--] followers, [--] engagements "Administration challenges like twice-daily dosing & low adherence impact #schizophrenia care. We're exploring the potential of LB-102 as a long-acting injectable (LAI) to improve adherence maintain drug levels & reduce relapse risk. Learn more: https://bit.ly/3EBIfUH https://bit.ly/3EBIfUH" [X Link](https://x.com/lb_pharma/status/1895126858439516558) 2025-02-27T15:00Z [--] followers, [--] engagements "What makes our candidate LB-102 stand out We offer a compelling balance of efficacy and safety which we believe will lead to improved treatment adherence. Discover the potential of LB-102 as a first-in-class antipsychotic benzamide in the United States: https://bit.ly/421o5g2 https://bit.ly/421o5g2" [X Link](https://x.com/lb_pharma/status/1901997130966794526) 2025-03-18T14:00Z [--] followers, [--] engagements "Dont miss our presentation at the upcoming [----] Congress of the Schizophrenia International Research Society (@SIRSGlobal). Learn more about the conference: https://bit.ly/4iMKtiG https://bit.ly/4iMKtiG" [X Link](https://x.com/lb_pharma/status/1905258590350229897) 2025-03-27T14:00Z [--] followers, [--] engagements "Treatment for #schizophrenia can be complicated as inconvenient dosing schedules and burdensome side effects make adherence challenging. Our investigational treatment LB-102 has the potential to simplify care. Check out our website for more: https://bit.ly/3EBIfUH https://bit.ly/3EBIfUH" [X Link](https://x.com/lb_pharma/status/1911781595725377581) 2025-04-14T14:00Z [--] followers, [--] engagements "Based on promising clinical trial results we are advancing our investigational treatment LB-102 as a first-in-class benzamide antipsychotic in the United States. Learn more about its potential as a novel therapy for #neuropsychiatric diseases: https://bit.ly/421o5g2 https://bit.ly/421o5g2" [X Link](https://x.com/lb_pharma/status/1912506445876035885) 2025-04-16T14:00Z [--] followers, [---] engagements "In our recent Phase [--] study our investigational treatment LB-102 was generally safe and well-tolerated as subjects experienced a low incidence of extrapyramidal symptoms (EPS) a side common effect of other available treatments. Learn more: https://lbpharma.us/lb-102-value-proposition/ https://lbpharma.us/lb-102-value-proposition/" [X Link](https://x.com/lb_pharma/status/1915767845490676105) 2025-04-25T14:00Z [--] followers, [---] engagements "Schizophrenia impacts 1% of adults in the United States. There is a need for improved and better tolerated treatments. That is why we're advancing our investigational treatment LB-102 for schizophrenia and other neuropsychiatric diseases: https://bit.ly/4obcrr3 https://bit.ly/4obcrr3" [X Link](https://x.com/lb_pharma/status/1991182232002728014) 2025-11-19T16:30Z [--] followers, [---] engagements "We're advancing our investigational therapy LB-102 into Phase [--] development in schizophrenia with the potential to provide once-daily dosing highly statistically significant PANSS reductions and a compelling safety and tolerability profile: https://bit.ly/3JYjKEc https://bit.ly/3JYjKEc" [X Link](https://x.com/lb_pharma/status/1991884527111668211) 2025-11-21T15:00Z [--] followers, [--] engagements "Bipolar depression affects [--] million people worldwide. New therapies to improve cognition and anhedonia reduce side effects and support better adherence are still needed. We are developing our investigational therapy LB-102 with this in mind: https://bit.ly/4obcrr3 https://bit.ly/4obcrr3" [X Link](https://x.com/lb_pharma/status/1992971708416852021) 2025-11-24T15:00Z [--] followers, [--] engagements "❄ Wishing our community a joyful holiday season Thank you for your support as we advance the development of LB-102 in schizophrenia bipolar depression & other neuropsychiatric diseases. From all of us at LB Pharma may your holidays be peaceful & your [----] filled with hope" [X Link](https://x.com/lb_pharma/status/2003167442059600274) 2025-12-22T18:15Z [--] followers, [--] engagements "In [----] we shared topline Phase [--] data successfully closed an IPO expanded our team & are poised to initiate schizophrenia and bipolar depression studies in [----]. We thank you for your support & look forward to continued advancement of LB-102 in 2026: https://bit.ly/4pMbHcR https://bit.ly/4pMbHcR" [X Link](https://x.com/lb_pharma/status/2005704146322636928) 2025-12-29T18:15Z [--] followers, [--] engagements "Dont miss us at #JPM26. Our CEO Heather Turner will join @endpts and @ky_lahucik for a fireside chat @LifeSciEvents and Gabrielle Masson for a panel with alongside industry leaders and will be busy with meetings and other events throughout the week. See you there" [X Link](https://x.com/lb_pharma/status/2009333058286002267) 2026-01-08T18:35Z [--] followers, [---] engagements "Check out our CEO Heather Turner discussing our progress including our recent IPO and the continued clinical advancement of LB-102 on @BiotechTV. Thanks @bradloncar for the thoughtful conversation on innovation in neuropsychiatric drug development and leadership in biotech : CEO Heather Turner tells us about the neuropsychiatric diseases medicine that enabled @lb_pharma to IPO in a tough market last year. $LBRX Full video: https://t.co/5JS29gQNI5 https://t.co/jpwWqARtEk : CEO Heather Turner tells us about the neuropsychiatric diseases medicine that enabled @lb_pharma to IPO in a tough" [X Link](https://x.com/lb_pharma/status/2012201922283905056) 2026-01-16T16:34Z [--] followers, [--] engagements "Our time at #JPM26 was productive. In addition to many investor and key partner meetings our CEO Heather Turner shared her perspective on our recent IPO todays capital markets and much more. Thank you to all who joined the conversations. Photography credit: Brian Benton" [X Link](https://x.com/lb_pharma/status/2014729938725654574) 2026-01-23T16:00Z [--] followers, [--] engagements "Bold innovation requires purpose-driven people. In our new #LBBold series we'll highlight the talented minds behind LB Pharma. Our Senior Director of Corporate Administration Lauren Stipp plays an important role in our success. Learn about our team: https://bit.ly/44IAYwv https://bit.ly/44IAYwv" [X Link](https://x.com/lb_pharma/status/2016170612482339256) 2026-01-27T15:25Z [--] followers, [--] engagements "Bipolar disorder affects an estimated 2.8% of Americans and remains a significant burden. We are advancing LB-102 an investigational therapy for #BipolarDepression in a recently initiated Phase [--] trial. Learn more: https://bit.ly/4qcV0bg https://bit.ly/4qcV0bg" [X Link](https://x.com/lb_pharma/status/2016554450450612412) 2026-01-28T16:50Z [--] followers, [--] engagements "We are focused on advancing our potential treatment for #schizophrenia and other neuropsychiatric disorders. Our CEO Heather Turner recently connected with @BenMComer about her career & how it has prepared her to further this mission at LB Pharmaceuticals: https://bit.ly/41riaQ8 https://bit.ly/41riaQ8" [X Link](https://x.com/lb_pharma/status/1897663624912535665) 2025-03-06T15:00Z [--] followers, [--] engagements "At the [----] Annual Congress of @SIRSGlobal we shared new data from the Phase [--] #ClinicalTrial of our investigational #schizophrenia treatment which reinforce the potential of our treatment to meaningfully reduce disease severity for patients. Read more: https://bit.ly/4hRAx6L https://bit.ly/4hRAx6L" [X Link](https://x.com/lb_pharma/status/1906693139017978101) 2025-03-31T13:00Z [--] followers, [---] engagements "We celebrated our IPO by ringing the @Nasdaq Closing Bell This milestone reflects our commitment to advancing our investigational therapy LB-102 for neuropsychiatric disorders. Thanks to all who made our IPO possible Watch here: $LBRX https://bit.ly/4oA3190 https://bit.ly/4oA3190" [X Link](https://x.com/lb_pharma/status/1983286433252049234) 2025-10-28T21:35Z [--] followers, [---] engagements "LB Pharmaceuticals Inc Announces Results of LB-102 Phase [--] First-in-Human Clinical Study #LB102 #schizophrenia #LBPharma https://www.businesswire.com/news/home/20200914005766/en/LB-Pharmaceuticals-Inc-Announces-Results-of-LB-102-Phase-1-First-in-Human-Clinical-Study https://www.businesswire.com/news/home/20200914005766/en/LB-Pharmaceuticals-Inc-Announces-Results-of-LB-102-Phase-1-First-in-Human-Clinical-Study" [X Link](https://x.com/lb_pharma/status/1305566016529989634) 2020-09-14T17:56Z [--] followers, [--] engagements "Just a reminder that tomorrow 11am ET we will be hosting the LB Pharmaceuticals Fall [----] Shareholders Conference Call. All shareholders & convertible noteholders should have received an email last week with the dial-in & link to slides. Please contact us if you need it resent" [X Link](https://x.com/lb_pharma/status/1316046600997830656) 2020-10-13T16:02Z [--] followers, [--] engagements "LB Pharmaceuticals Announces the Initiation of Patient Dosing in Open Label Phase 1b Imaging Study of LB-102 #Schizophrenia #LB102 https://www.businesswire.com/news/home/20210202006104/en/LB-Pharmaceuticals-Announces-the-Initiation-of-Patient-Dosing-in-Open-Label-Phase-1b-Imaging-Study-of-LB-102 https://www.businesswire.com/news/home/20210202006104/en/LB-Pharmaceuticals-Announces-the-Initiation-of-Patient-Dosing-in-Open-Label-Phase-1b-Imaging-Study-of-LB-102" [X Link](https://x.com/lb_pharma/status/1356712506425815043) 2021-02-02T21:14Z [--] followers, [--] engagements "LB Pharmaceuticals To Participate in the B. Riley Securities Neuroscience Conference - 9:30am ET Thursday April 29th. This will be our first presentation at a Wall St #lifescience conference https://www.businesswire.com/news/home/20210426005628/en/LB-Pharmaceuticals-To-Participate-in-the-B.-Riley-Securities%E2%80%99-Neuroscience-Conference https://www.businesswire.com/news/home/20210426005628/en/LB-Pharmaceuticals-To-Participate-in-the-B.-Riley-Securities%E2%80%99-Neuroscience-Conference" [X Link](https://x.com/lb_pharma/status/1386700481637060612) 2021-04-26T15:15Z [--] followers, [--] engagements "LB Pharmaceuticals Announces Publication of Phase [--] Clinical Study of LB-102 "This clinical study enrolled [--] healthy volunteers and was the first time LB-102 had been dosed in humans." https://www.businesswire.com/news/home/20220719005932/en/LB-Announces-Publication-of-Phase-1-Clinical-Study-of-LB-102 https://www.businesswire.com/news/home/20220719005932/en/LB-Announces-Publication-of-Phase-1-Clinical-Study-of-LB-102" [X Link](https://x.com/lb_pharma/status/1549411942984564738) 2022-07-19T15:12Z [--] followers, [--] engagements "Gad Soffer joins as CBO and Richard Silva Ph.D. as SVP of Technical Operations Their expertise in business strategy CMC & manufacturing will be key in advancing LB-102 to potentially bring safer treatments to patients with #schizophrenia. Read more: https://bit.ly/4hPVmQl https://bit.ly/4hPVmQl" [X Link](https://x.com/lb_pharma/status/1889308438938702011) 2025-02-11T13:40Z [--] followers, [--] engagements "We look forward to presenting [--] posters at #ECNP2025 highlighting clinical activity & safety profile of LB-102 in #schizophrenia including new data showing positive effects on cognition & negative symptoms. Read more in our press release: @ecnptweets https://bit.ly/4q6tHj2 https://bit.ly/4q6tHj2" [X Link](https://x.com/lb_pharma/status/1977041739442483434) 2025-10-11T16:00Z [--] followers, [---] engagements "At #ECNP2025 we highlighted data showing the clinical activity & safety profile of our investigational treatment LB-102 in schizophrenia. The results include positive effects on cognition and negative symptoms. Review all [--] posters on our website: $LBRX https://bit.ly/3W50E1L https://bit.ly/3W50E1L" [X Link](https://x.com/lb_pharma/status/1977751383638999142) 2025-10-13T15:00Z [--] followers, [---] engagements "James Rawls Pharm.D. joins us as SVP Regulatory Affairs. His FDA & global CNS regulatory experience make him a great addition to our team as we aim to advance LB-102 as a potential treatment for neuropsychiatric disorders in the US: https://bit.ly/4hazmkg https://bit.ly/4hazmkg" [X Link](https://x.com/lb_pharma/status/1978106089343271412) 2025-10-14T14:30Z [--] followers, [---] engagements "Today we reported third quarter [----] financial results. Read the full press release here: https://bit.ly/4oZuLUM https://bit.ly/4oZuLUM" [X Link](https://x.com/lb_pharma/status/1986444762073735235) 2025-11-06T14:45Z [--] followers, [--] engagements "Today we welcome Kaya Pai Panandiker a seasoned industry leader with 20+ years of global biopharmaceutical experience as our new Chief Commercial Officer. Her work launching successful neuroscience brands will be key as we advance LB-102. Read more: https://bit.ly/49MmKOn https://bit.ly/49MmKOn" [X Link](https://x.com/lb_pharma/status/1988603987549917436) 2025-11-12T13:45Z [--] followers, [--] engagements "Our CEO Heather Turner joined The Biohub podcast with Tom Weir to share her journey from law to biotech leadership and discuss LB Pharmaceuticals mission to advance treatments for schizophrenia and bipolar depression. Watch here: https://bit.ly/49MIee2 https://bit.ly/49MIee2" [X Link](https://x.com/lb_pharma/status/1989347796197974098) 2025-11-14T15:00Z [--] followers, [---] engagements "Next week our CEO Heather Turner will present at the Piper Sandler 37th Annual Healthcare Conference. Find the details in our press release: $LBRX https://bit.ly/4pvJjM5 https://bit.ly/4pvJjM5" [X Link](https://x.com/lb_pharma/status/1992981310055309359) 2025-11-24T15:39Z [--] followers, [---] engagements "Were deeply grateful to our incredible team at LB Pharmaceuticals for their dedication passion and commitment to advancing treatments that make a difference for patients. Your work drives our mission every day. Learn more about our work: https://bit.ly/49h3qJc https://bit.ly/49h3qJc" [X Link](https://x.com/lb_pharma/status/1993696389310665036) 2025-11-26T15:00Z [--] followers, [--] engagements "Later this month LB Pharmaceuticals will be added to the Russell [----] Index and the broad-market Russell [----] Index as part of the [----] Russell indexes reconstitution. Learn more in our press release: $LBRX https://bit.ly/48DdlGQ https://bit.ly/48DdlGQ" [X Link](https://x.com/lb_pharma/status/1998414906215874739) 2025-12-09T15:30Z [--] followers, [---] engagements "In October we rang the @Nasdaq closing bell & connected with Kristina Ayanian at Live from MarketSite to talk about our recent IPO whats unique about our lead product candidate LB-102 and whats ahead for LB Pharma. 🎥 Watch the full interview here: https://bit.ly/3YdB37D https://bit.ly/3YdB37D" [X Link](https://x.com/lb_pharma/status/1998783314627330548) 2025-12-10T15:54Z [--] followers, [--] engagements "We welcome Ellen Rose as SVP Corporate Affairs and Lindsay Beaupre as SVP People and Culture to LB Pharmaceuticals. Their leadership strengthens our team as we advance LB-102 for #NeuropsychiatricDiseases. Read more in our press release: https://bit.ly/3Ytgi8l https://bit.ly/3Ytgi8l" [X Link](https://x.com/lb_pharma/status/2008542887114396009) 2026-01-06T14:15Z [--] followers, [--] engagements "We will be at @ACNPorgs #ACNP2026. We look forward to engaging with the #Neuroscience community and discussing progress in advancing innovative treatments for #NeuropsychiatricDisorders such as our investigational treatment LB-102" [X Link](https://x.com/lb_pharma/status/2010777592979149023) 2026-01-12T18:15Z [--] followers, [---] engagements "We are pleased to welcome Dr. Minako Pazdera to the LB Pharmaceuticals leadership team as General Counsel. She brings 25+ years of experience in governance IP transactions compliance and will support the continued advancement of LB-102. Read more here: https://bit.ly/49RGAXa https://bit.ly/49RGAXa" [X Link](https://x.com/lb_pharma/status/2013976904471105647) 2026-01-21T14:08Z [--] followers, [--] engagements "We have initiated ILLUMINATE-1 a Phase [--] trial evaluating our investigational oral small molecule LB-102 in #BipolarDepression. This is an important step in advancing the development program for LB-102 to include mood disorders. Read more: $LBRX https://bit.ly/4662RPN https://bit.ly/4662RPN" [X Link](https://x.com/lb_pharma/status/2015787024628809776) 2026-01-26T14:00Z [--] followers, [---] engagements "With new funding secured we intend to explore the potential of our investigational oral small molecule LB-102 as an adjunctive treatment for major depressive disorder in a Phase [--] trial. Learn more: $LBRX https://bit.ly/4tBj7CL https://bit.ly/4tBj7CL" [X Link](https://x.com/lb_pharma/status/2019405413561647533) 2026-02-05T13:39Z [--] followers, [---] engagements "On International Day of Women and Girls in Science we recognize the women of LB Pharma who represent 65% of our team and advance science with inclusive leadership and diverse perspectives. Learn more about #IDWGIS: #WomenInScience #EveryVoiceinScience https://bit.ly/4hKylyA https://bit.ly/4hKylyA" [X Link](https://x.com/lb_pharma/status/2021641709361185189) 2026-02-11T17:45Z [--] followers, [--] engagements Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing
@lb_pharma LB Pharmaceuticals
LB Pharmaceuticals posts on X about ceo, $lbrx, ipo, we are the most. They currently have [--] followers and [--] posts still getting attention that total [--] engagements in the last [--] hours.
Engagements: [--] #
- [--] Week [---] -72%
- [--] Month [-----] +125%
- [--] Months [-----] +215%
- [--] Year [-----] +7,096%
Mentions: [--] #
- [--] Week [--] +13%
- [--] Month [--] +275%
- [--] Months [--] +200%
- [--] Year [--] +4,200%
Followers: [--] #
- [--] Week [--] no change
- [--] Month [--] +2.40%
CreatorRank: undefined #
Social Influence
Social category influence stocks finance countries exchanges
Social topic influence ceo, $lbrx #2, ipo, we are, release, advance, reduce, united states, study, check out
Top accounts mentioned or mentioned by @kylahucik @endpts @sirsglobal @biotechtv @nasdaq @drugtargetrev @hcplivenews @lifescievents @bradloncar @lbpharma @benmcomer @ecnptweets @acnporgs
Top assets mentioned LB Pharmaceuticals Inc. (LBRX) Dana Incorporated (DAN)
Top Social Posts
Top posts by engagements in the last [--] hours
"Making progress #LB102 #schizophrenia"
X Link 2021-04-01T14:28Z [--] followers, [--] engagements
"We just received a Notice of Allowance from South Korea (Patent Application No. 10-2019-7018269) #Schizophrenia #patent #LB102"
X Link 2021-05-19T16:59Z [--] followers, [--] engagements
"LB Pharmaceuticals Presents Results of Dopamine Receptor Occupancy Studies of LB-102 at ECNP Conference #LBPharma #Schizophrenia #ECNP2021 #mentalhealth https://www.businesswire.com/news/home/20211004005645/en/LB-Pharmaceuticals-Presents-Results-of-Dopamine-Receptor-Occupancy-Studies-of-LB-102-at-ECNP-Conference https://www.businesswire.com/news/home/20211004005645/en/LB-Pharmaceuticals-Presents-Results-of-Dopamine-Receptor-Occupancy-Studies-of-LB-102-at-ECNP-Conference"
X Link 2021-10-04T14:49Z [--] followers, [--] engagements
"Nearly 50% of #schizophrenia patients fail to respond adequately to existing therapies. There is an immense need for new treatments. We aim to combat this unmet need and bring hope to those who need it most. Learn more about schizophrenia here: https://bit.ly/41d4Qjg https://bit.ly/41d4Qjg"
X Link 2025-02-19T15:00Z [--] followers, [--] engagements
"This #BrainAwarenessWeek we highlight the complexity of the brain and the need for continued innovation in brain health as it relates to the development of new treatments for #psychiatric diseases like #schizophrenia. Learn more from the Dana Foundation: https://bit.ly/3IiRQOJ https://bit.ly/3IiRQOJ"
X Link 2025-03-10T17:45Z [--] followers, [---] engagements
"Our CEO Heather Turner was featured in @DrugTargetRev discussing our first-in-class investigational treatment LB-102 which recently showed strong results in a Phase [--] study evaluating its potential as a new therapy for #schizophrenia. Read here: https://bit.ly/3RYnl5s https://bit.ly/3RYnl5s"
X Link 2025-04-22T13:00Z [--] followers, [---] engagements
"Our lead investigator John M. Kane MD spoke to @HCPLiveNews about LB-102 our investigational treatment for acute #schizophrenia that demonstrated promising efficacy safety and tolerability in our recently completed Phase [--] clinical trial. Watch here: https://bit.ly/42Iz1hR https://bit.ly/42Iz1hR"
X Link 2025-04-28T14:00Z [--] followers, [---] engagements
"Our CEO Heather Turner recently spoke with @ky_lahucik of @endpts about our IPO and how the new funding positions us to initiate a Phase [--] trial in #schizophrenia and a Phase [--] trial in #BipolarDepression in [----]. Read more: https://bit.ly/473DJZS https://bit.ly/473DJZS"
X Link 2025-10-10T20:00Z [--] followers, [--] engagements
"LB Pharma Initiates Phase [--] Clinical Trial for LB-102 #LBPharma #schizophrenia #brainhealth #LB102 https://www.businesswire.com/news/home/20200122005022/en/LB-Pharmaceuticals-Announces-Initiation-Patient-Dosing-First-in-Human https://www.businesswire.com/news/home/20200122005022/en/LB-Pharmaceuticals-Announces-Initiation-Patient-Dosing-First-in-Human"
X Link 2020-01-22T13:52Z [--] followers, [--] engagements
"LB Pharmaceuticals Inc Announces the Hiring of Dr. Anna Eramo as Chief Medical Officer #LBPharma #LB102 #Schizophrenia https://www.businesswire.com/news/home/20200902005783/en/LB-Pharmaceuticals-Announces-Hiring-Dr.-Anna-Eramo https://www.businesswire.com/news/home/20200902005783/en/LB-Pharmaceuticals-Announces-Hiring-Dr.-Anna-Eramo"
X Link 2020-09-02T16:13Z [--] followers, [--] engagements
"Administration challenges like twice-daily dosing & low adherence impact #schizophrenia care. We're exploring the potential of LB-102 as a long-acting injectable (LAI) to improve adherence maintain drug levels & reduce relapse risk. Learn more: https://bit.ly/3EBIfUH https://bit.ly/3EBIfUH"
X Link 2025-02-27T15:00Z [--] followers, [--] engagements
"What makes our candidate LB-102 stand out We offer a compelling balance of efficacy and safety which we believe will lead to improved treatment adherence. Discover the potential of LB-102 as a first-in-class antipsychotic benzamide in the United States: https://bit.ly/421o5g2 https://bit.ly/421o5g2"
X Link 2025-03-18T14:00Z [--] followers, [--] engagements
"Dont miss our presentation at the upcoming [----] Congress of the Schizophrenia International Research Society (@SIRSGlobal). Learn more about the conference: https://bit.ly/4iMKtiG https://bit.ly/4iMKtiG"
X Link 2025-03-27T14:00Z [--] followers, [--] engagements
"Treatment for #schizophrenia can be complicated as inconvenient dosing schedules and burdensome side effects make adherence challenging. Our investigational treatment LB-102 has the potential to simplify care. Check out our website for more: https://bit.ly/3EBIfUH https://bit.ly/3EBIfUH"
X Link 2025-04-14T14:00Z [--] followers, [--] engagements
"Based on promising clinical trial results we are advancing our investigational treatment LB-102 as a first-in-class benzamide antipsychotic in the United States. Learn more about its potential as a novel therapy for #neuropsychiatric diseases: https://bit.ly/421o5g2 https://bit.ly/421o5g2"
X Link 2025-04-16T14:00Z [--] followers, [---] engagements
"In our recent Phase [--] study our investigational treatment LB-102 was generally safe and well-tolerated as subjects experienced a low incidence of extrapyramidal symptoms (EPS) a side common effect of other available treatments. Learn more: https://lbpharma.us/lb-102-value-proposition/ https://lbpharma.us/lb-102-value-proposition/"
X Link 2025-04-25T14:00Z [--] followers, [---] engagements
"Schizophrenia impacts 1% of adults in the United States. There is a need for improved and better tolerated treatments. That is why we're advancing our investigational treatment LB-102 for schizophrenia and other neuropsychiatric diseases: https://bit.ly/4obcrr3 https://bit.ly/4obcrr3"
X Link 2025-11-19T16:30Z [--] followers, [---] engagements
"We're advancing our investigational therapy LB-102 into Phase [--] development in schizophrenia with the potential to provide once-daily dosing highly statistically significant PANSS reductions and a compelling safety and tolerability profile: https://bit.ly/3JYjKEc https://bit.ly/3JYjKEc"
X Link 2025-11-21T15:00Z [--] followers, [--] engagements
"Bipolar depression affects [--] million people worldwide. New therapies to improve cognition and anhedonia reduce side effects and support better adherence are still needed. We are developing our investigational therapy LB-102 with this in mind: https://bit.ly/4obcrr3 https://bit.ly/4obcrr3"
X Link 2025-11-24T15:00Z [--] followers, [--] engagements
"❄ Wishing our community a joyful holiday season Thank you for your support as we advance the development of LB-102 in schizophrenia bipolar depression & other neuropsychiatric diseases. From all of us at LB Pharma may your holidays be peaceful & your [----] filled with hope"
X Link 2025-12-22T18:15Z [--] followers, [--] engagements
"In [----] we shared topline Phase [--] data successfully closed an IPO expanded our team & are poised to initiate schizophrenia and bipolar depression studies in [----]. We thank you for your support & look forward to continued advancement of LB-102 in 2026: https://bit.ly/4pMbHcR https://bit.ly/4pMbHcR"
X Link 2025-12-29T18:15Z [--] followers, [--] engagements
"Dont miss us at #JPM26. Our CEO Heather Turner will join @endpts and @ky_lahucik for a fireside chat @LifeSciEvents and Gabrielle Masson for a panel with alongside industry leaders and will be busy with meetings and other events throughout the week. See you there"
X Link 2026-01-08T18:35Z [--] followers, [---] engagements
"Check out our CEO Heather Turner discussing our progress including our recent IPO and the continued clinical advancement of LB-102 on @BiotechTV. Thanks @bradloncar for the thoughtful conversation on innovation in neuropsychiatric drug development and leadership in biotech : CEO Heather Turner tells us about the neuropsychiatric diseases medicine that enabled @lb_pharma to IPO in a tough market last year. $LBRX Full video: https://t.co/5JS29gQNI5 https://t.co/jpwWqARtEk : CEO Heather Turner tells us about the neuropsychiatric diseases medicine that enabled @lb_pharma to IPO in a tough"
X Link 2026-01-16T16:34Z [--] followers, [--] engagements
"Our time at #JPM26 was productive. In addition to many investor and key partner meetings our CEO Heather Turner shared her perspective on our recent IPO todays capital markets and much more. Thank you to all who joined the conversations. Photography credit: Brian Benton"
X Link 2026-01-23T16:00Z [--] followers, [--] engagements
"Bold innovation requires purpose-driven people. In our new #LBBold series we'll highlight the talented minds behind LB Pharma. Our Senior Director of Corporate Administration Lauren Stipp plays an important role in our success. Learn about our team: https://bit.ly/44IAYwv https://bit.ly/44IAYwv"
X Link 2026-01-27T15:25Z [--] followers, [--] engagements
"Bipolar disorder affects an estimated 2.8% of Americans and remains a significant burden. We are advancing LB-102 an investigational therapy for #BipolarDepression in a recently initiated Phase [--] trial. Learn more: https://bit.ly/4qcV0bg https://bit.ly/4qcV0bg"
X Link 2026-01-28T16:50Z [--] followers, [--] engagements
"We are focused on advancing our potential treatment for #schizophrenia and other neuropsychiatric disorders. Our CEO Heather Turner recently connected with @BenMComer about her career & how it has prepared her to further this mission at LB Pharmaceuticals: https://bit.ly/41riaQ8 https://bit.ly/41riaQ8"
X Link 2025-03-06T15:00Z [--] followers, [--] engagements
"At the [----] Annual Congress of @SIRSGlobal we shared new data from the Phase [--] #ClinicalTrial of our investigational #schizophrenia treatment which reinforce the potential of our treatment to meaningfully reduce disease severity for patients. Read more: https://bit.ly/4hRAx6L https://bit.ly/4hRAx6L"
X Link 2025-03-31T13:00Z [--] followers, [---] engagements
"We celebrated our IPO by ringing the @Nasdaq Closing Bell This milestone reflects our commitment to advancing our investigational therapy LB-102 for neuropsychiatric disorders. Thanks to all who made our IPO possible Watch here: $LBRX https://bit.ly/4oA3190 https://bit.ly/4oA3190"
X Link 2025-10-28T21:35Z [--] followers, [---] engagements
"LB Pharmaceuticals Inc Announces Results of LB-102 Phase [--] First-in-Human Clinical Study #LB102 #schizophrenia #LBPharma https://www.businesswire.com/news/home/20200914005766/en/LB-Pharmaceuticals-Inc-Announces-Results-of-LB-102-Phase-1-First-in-Human-Clinical-Study https://www.businesswire.com/news/home/20200914005766/en/LB-Pharmaceuticals-Inc-Announces-Results-of-LB-102-Phase-1-First-in-Human-Clinical-Study"
X Link 2020-09-14T17:56Z [--] followers, [--] engagements
"Just a reminder that tomorrow 11am ET we will be hosting the LB Pharmaceuticals Fall [----] Shareholders Conference Call. All shareholders & convertible noteholders should have received an email last week with the dial-in & link to slides. Please contact us if you need it resent"
X Link 2020-10-13T16:02Z [--] followers, [--] engagements
"LB Pharmaceuticals Announces the Initiation of Patient Dosing in Open Label Phase 1b Imaging Study of LB-102 #Schizophrenia #LB102 https://www.businesswire.com/news/home/20210202006104/en/LB-Pharmaceuticals-Announces-the-Initiation-of-Patient-Dosing-in-Open-Label-Phase-1b-Imaging-Study-of-LB-102 https://www.businesswire.com/news/home/20210202006104/en/LB-Pharmaceuticals-Announces-the-Initiation-of-Patient-Dosing-in-Open-Label-Phase-1b-Imaging-Study-of-LB-102"
X Link 2021-02-02T21:14Z [--] followers, [--] engagements
"LB Pharmaceuticals To Participate in the B. Riley Securities Neuroscience Conference - 9:30am ET Thursday April 29th. This will be our first presentation at a Wall St #lifescience conference https://www.businesswire.com/news/home/20210426005628/en/LB-Pharmaceuticals-To-Participate-in-the-B.-Riley-Securities%E2%80%99-Neuroscience-Conference https://www.businesswire.com/news/home/20210426005628/en/LB-Pharmaceuticals-To-Participate-in-the-B.-Riley-Securities%E2%80%99-Neuroscience-Conference"
X Link 2021-04-26T15:15Z [--] followers, [--] engagements
"LB Pharmaceuticals Announces Publication of Phase [--] Clinical Study of LB-102 "This clinical study enrolled [--] healthy volunteers and was the first time LB-102 had been dosed in humans." https://www.businesswire.com/news/home/20220719005932/en/LB-Announces-Publication-of-Phase-1-Clinical-Study-of-LB-102 https://www.businesswire.com/news/home/20220719005932/en/LB-Announces-Publication-of-Phase-1-Clinical-Study-of-LB-102"
X Link 2022-07-19T15:12Z [--] followers, [--] engagements
"Gad Soffer joins as CBO and Richard Silva Ph.D. as SVP of Technical Operations Their expertise in business strategy CMC & manufacturing will be key in advancing LB-102 to potentially bring safer treatments to patients with #schizophrenia. Read more: https://bit.ly/4hPVmQl https://bit.ly/4hPVmQl"
X Link 2025-02-11T13:40Z [--] followers, [--] engagements
"We look forward to presenting [--] posters at #ECNP2025 highlighting clinical activity & safety profile of LB-102 in #schizophrenia including new data showing positive effects on cognition & negative symptoms. Read more in our press release: @ecnptweets https://bit.ly/4q6tHj2 https://bit.ly/4q6tHj2"
X Link 2025-10-11T16:00Z [--] followers, [---] engagements
"At #ECNP2025 we highlighted data showing the clinical activity & safety profile of our investigational treatment LB-102 in schizophrenia. The results include positive effects on cognition and negative symptoms. Review all [--] posters on our website: $LBRX https://bit.ly/3W50E1L https://bit.ly/3W50E1L"
X Link 2025-10-13T15:00Z [--] followers, [---] engagements
"James Rawls Pharm.D. joins us as SVP Regulatory Affairs. His FDA & global CNS regulatory experience make him a great addition to our team as we aim to advance LB-102 as a potential treatment for neuropsychiatric disorders in the US: https://bit.ly/4hazmkg https://bit.ly/4hazmkg"
X Link 2025-10-14T14:30Z [--] followers, [---] engagements
"Today we reported third quarter [----] financial results. Read the full press release here: https://bit.ly/4oZuLUM https://bit.ly/4oZuLUM"
X Link 2025-11-06T14:45Z [--] followers, [--] engagements
"Today we welcome Kaya Pai Panandiker a seasoned industry leader with 20+ years of global biopharmaceutical experience as our new Chief Commercial Officer. Her work launching successful neuroscience brands will be key as we advance LB-102. Read more: https://bit.ly/49MmKOn https://bit.ly/49MmKOn"
X Link 2025-11-12T13:45Z [--] followers, [--] engagements
"Our CEO Heather Turner joined The Biohub podcast with Tom Weir to share her journey from law to biotech leadership and discuss LB Pharmaceuticals mission to advance treatments for schizophrenia and bipolar depression. Watch here: https://bit.ly/49MIee2 https://bit.ly/49MIee2"
X Link 2025-11-14T15:00Z [--] followers, [---] engagements
"Next week our CEO Heather Turner will present at the Piper Sandler 37th Annual Healthcare Conference. Find the details in our press release: $LBRX https://bit.ly/4pvJjM5 https://bit.ly/4pvJjM5"
X Link 2025-11-24T15:39Z [--] followers, [---] engagements
"Were deeply grateful to our incredible team at LB Pharmaceuticals for their dedication passion and commitment to advancing treatments that make a difference for patients. Your work drives our mission every day. Learn more about our work: https://bit.ly/49h3qJc https://bit.ly/49h3qJc"
X Link 2025-11-26T15:00Z [--] followers, [--] engagements
"Later this month LB Pharmaceuticals will be added to the Russell [----] Index and the broad-market Russell [----] Index as part of the [----] Russell indexes reconstitution. Learn more in our press release: $LBRX https://bit.ly/48DdlGQ https://bit.ly/48DdlGQ"
X Link 2025-12-09T15:30Z [--] followers, [---] engagements
"In October we rang the @Nasdaq closing bell & connected with Kristina Ayanian at Live from MarketSite to talk about our recent IPO whats unique about our lead product candidate LB-102 and whats ahead for LB Pharma. 🎥 Watch the full interview here: https://bit.ly/3YdB37D https://bit.ly/3YdB37D"
X Link 2025-12-10T15:54Z [--] followers, [--] engagements
"We welcome Ellen Rose as SVP Corporate Affairs and Lindsay Beaupre as SVP People and Culture to LB Pharmaceuticals. Their leadership strengthens our team as we advance LB-102 for #NeuropsychiatricDiseases. Read more in our press release: https://bit.ly/3Ytgi8l https://bit.ly/3Ytgi8l"
X Link 2026-01-06T14:15Z [--] followers, [--] engagements
"We will be at @ACNPorgs #ACNP2026. We look forward to engaging with the #Neuroscience community and discussing progress in advancing innovative treatments for #NeuropsychiatricDisorders such as our investigational treatment LB-102"
X Link 2026-01-12T18:15Z [--] followers, [---] engagements
"We are pleased to welcome Dr. Minako Pazdera to the LB Pharmaceuticals leadership team as General Counsel. She brings 25+ years of experience in governance IP transactions compliance and will support the continued advancement of LB-102. Read more here: https://bit.ly/49RGAXa https://bit.ly/49RGAXa"
X Link 2026-01-21T14:08Z [--] followers, [--] engagements
"We have initiated ILLUMINATE-1 a Phase [--] trial evaluating our investigational oral small molecule LB-102 in #BipolarDepression. This is an important step in advancing the development program for LB-102 to include mood disorders. Read more: $LBRX https://bit.ly/4662RPN https://bit.ly/4662RPN"
X Link 2026-01-26T14:00Z [--] followers, [---] engagements
"With new funding secured we intend to explore the potential of our investigational oral small molecule LB-102 as an adjunctive treatment for major depressive disorder in a Phase [--] trial. Learn more: $LBRX https://bit.ly/4tBj7CL https://bit.ly/4tBj7CL"
X Link 2026-02-05T13:39Z [--] followers, [---] engagements
"On International Day of Women and Girls in Science we recognize the women of LB Pharma who represent 65% of our team and advance science with inclusive leadership and diverse perspectives. Learn more about #IDWGIS: #WomenInScience #EveryVoiceinScience https://bit.ly/4hKylyA https://bit.ly/4hKylyA"
X Link 2026-02-11T17:45Z [--] followers, [--] engagements
Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing